You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Claims for Patent: 11,717,555

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,717,555

Title:	Pharmaceutical compositions having a selected release duration
Abstract:	The present invention provides for a stabilized biodegradable polymeric composition useful as a controlled release delivery system for peptide agents. The compositions of the present invention comprise a) a strong acid salt of a LHRH agonist or antagonist; b) a biodegradable polymer of poly(lactide-co-glycolide), wherein the ratio of lactide:glycolide of the copolymer is from 50:50 to about 100:0; and c) N-methyl-2-pyrrolidone (NMP), wherein the composition does not contain excess strong acid in addition to the strong acid used to form the salt of the LHRH agonist or antagonist. The composition, when injected, can provide a controlled release of leuprolide for a period of up to 6 months.
Inventor(s):	Yuhua Li, Andrew Guarino
Assignee:	Foresee Pharmaceuticals Co Ltd
Application Number:	US16/954,984
Patent Claims:	1. A pharmaceutical composition comprising: a) a combination of a strong acid salt and a weak acid salt of a luteinizing hormone releasing hormone (LHRH) agonist wherein the molar ratio of (strong acid salt anion+weak acid salt anion) to the LHRH agonist is ≤2:1 and the molar ratio of the strong acid salt anion to the LHRH agonist is from 1:1 to less than 2:1; b) a biodegradable polymer selected from the group consisting of a homopolymer polylatic acid (PLA), and a copolymer poly (lactic acid-co-glycolic acid) (PLGA), wherein the ratio of lactic acid:glycolic acid of the copolymer is from 50:50 to 100:0; and c) N-methyl-2-pyrrolidone (NMP), wherein: the pharmaceutical composition has a selected release duration ranging from one month to 6 months, which correlates with ratios of the strong acid salt anion and the weak acid salt anion of the LHRH agonist; the LHRH agonist is selected from the group consisting of leuprolide, triptorelin, and goserelin; and the strong acid is methanesulfonic acid or hydrochloric acid, and the weak acid is acetic acid or formic acid. 2. The pharmaceutical composition of claim 1 wherein the LHRH agonist is leuprolide. 3. The pharmaceutical composition of claim 1 wherein the strong acid is methanesulfonic acid. 4. The pharmaceutical composition of claim 1 wherein the weak acid is formic acid. 5. The pharmaceutical composition of claim 1, wherein the strong acid salt is leuprolide mesylate, and the weak acid salt is leuprolide acetate. 6. The pharmaceutical composition of claim 5 wherein the molar ratio of mesylate anion to leuprolide is from 1.4:1 to less than 2:1. 7. The pharmaceutical composition of claim 5 wherein the molar ratio of mesylate anion to leuprolide is from 1.5:1 to 1.8:1. 8. A pharmaceutical composition comprising: a) a combination of leuprolide mesylate and leuprolide formate, wherein the molar ratio of (mesylate+formate) to leuprolide is ≤2:1 and the molar ratio of mesylate anion to leuprolide is from 1:1 to less than 2:1; b) a biodegradable polymer selected from the group consisting of a homopolymer polylatic acid (PLA), and a copolymer poly (lactic acid-co-glycolic acid) (PLGA), wherein the ratio of lactic acid:glycolic acid of the copolymer is from 50:50 to 100:0; and c) N-methyl-2-pyrrolidone (NMP); wherein the pharmaceutical composition has a selected release duration ranging from one month to 6 months, which correlate with ratios of mesylate to leuprolide. 9. The pharmaceutical composition of claim 8 wherein the molar ratio of mesylate anion to leuprolide is from 1.4:1 to less than 2:1. 10. The pharmaceutical composition of claim 8 wherein the molar ratio of mesylate anion to leuprolide is from 1.5:1 to 1.8:1. 11. The pharmaceutical composition of claim 1 wherein the biodegradable polymer has at least one hydroxyl terminal group. 12. The pharmaceutical composition of claim 5 wherein the biodegradable polymer has at least one hydroxyl terminal group. 13. The pharmaceutical composition of claim 8 wherein the biodegradable polymer has at least one hydroxyl terminal group. 14. The pharmaceutical composition of claim 1 wherein the pharmaceutical composition has 30 to 60% of the biodegradable polymer of the composition by weight, and a polydispersity less than or equal to 2.5. 15. The pharmaceutical composition of claim 14 wherein the biodegradable polymer has an average molecular weight of 8,000 to 50,000 Daltons.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.